Comparison of fusion calling platforms in pediatric DIPG and high‐grade glioma

In this proposal, we will collaborate with theChildren’s Brain Tumor Tissue Consortium (CBTTC) to compare the CODAC tool against other established computational tools on the RNA-sequencing data of over 100 DIPG tumors. To confirm that fusions called by the CODAC pipeline are tumor driving (not false positives), we will model them in various in vitro and in vivo (mouse) genetically engineered models. For confirmed tumorigenic fusions, we will treat these models with pathway relevant therapies.